Advanced Search

Study Preview



Study Title and Description

Year-by-year analysis of cardiovascular events in the Multiple Outcomes of Raloxifene Evaluation (MORE) trial.



Key Questions Addressed
2 Key Question 2. In adult women without preexisting breast cancer, what is the effectiveness and comparative effectiveness of medications to reduce risk for primary breast cancer on improvement in short- and long-term health outcomes, including invasive breast cancer, noninvasive breast cancer (including ductal carcinoma in situ), breast cancer mortality, all-cause mortality, and other beneficial outcomes (such as reduced fractures caused by certain medications and improved quality of life)? Key Question 2a. Does the effectiveness of risk-reducing medications vary by timing of initiation or duration of use? Key Question 2b. Does the effectiveness of risk-reducing medications persist beyond discontinuation of use?
  • Comments Comments (
    0
    ) |
3 Key Question 3. What are the harms of using medications to reduce risk for primary breast cancer? Key Question 3a. Do harms of risk-reducing medications vary by timing of initiation and/or duration of use? Key Question 3b. Do harms of risk-reducing medications persist beyond discontinuation of use?
  • Comments Comments (
    0
    ) |

Primary Publication Information
  • Comments Comments (
    0
    ) |
TitleData
Title Year-by-year analysis of cardiovascular events in the Multiple Outcomes of Raloxifene Evaluation (MORE) trial.
Author Keech CA., Sashegyi A., Barrett-Connor E.
Country Eli Lilly and Company, Indianapolis, IN, USA.
Year 2005
Numbers Pubmed ID: 15881485

Secondary Publication Information
There are currently no secondary publications defined for this study.


Extraction Form: Key Questions 1-4


Results & Comparisons

No Results found.